National Institute on Drug Abuse; Notice of Closed Meeting, 2536-2537 [2019-01412]

Download as PDF 2536 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Immunology Integrated Review Group; Immunity and Host Defense Study Section. Date: February 21–22, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bahia Resort Hotel, 998 West Mission Bay Drive, San Diego, CA 92109. Contact Person: Scott Jakes, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4198, MSC 7812, Bethesda, MD 20892, 301–435– 1506, jakesse@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 2, 2019. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–01460 Filed 2–6–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and VerDate Sep<11>2014 17:23 Feb 06, 2019 Jkt 247001 the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Cancer, Heart, and Sleep Epidemiology A Study Section. Date: February 21–22, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Sir Francis Drake Hotel, 450 Powell Street at Sutter, San Francisco, CA 94102. Contact Person: Denise Wiesch, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3138, MSC 7770, Bethesda, MD 20892, (301) 437– 3478, wieschd@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 1, 2019. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–01403 Filed 2–6–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Integrative Health; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the ZAT1 AJT (10) meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; NCCIH Training and Education Review Panel (CT). Date: March 26, 2019. Time: 11:00 a.m. to 5:00 p.m. PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Ashlee Tipton, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Center for Complementary and Integrative Health, 6707 Democracy Boulevard, Room 401, Bethesda, MD 20892, 301–451–3849, ashlee.tipton@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS) Dated: February 1, 2019. Ron Livingston, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–01410 Filed 2–6–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Improving Implementation of Seek, Test, Treat & Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01—Clinical Trial Required). Date: February 19, 2019. Time: 10:00 p.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301–827–5820, hiromi.ono@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and E:\FR\FM\07FEN1.SGM 07FEN1 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices Addiction Research Programs, National Institutes of Health, HHS) Dated: February 1, 2019. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–01412 Filed 2–6–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Ziopharm Oncology, Inc. (‘‘Ziopharm’’), headquartered in Boston, MA. SUMMARY: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before February 22, 2019 will be considered. DATES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm. 1E530, MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702; Telephone: (240)–276–5484; Facsimile: (240)–276–5504; Email: andy.burke@nih.gov. ADDRESSES: SUPPLEMENTARY INFORMATION: Intellectual Property Group A E–028–2015: Anti-Mutated KRAS T Cell Receptors 1. US Provisional Patent Application 62/084,654, filed November 26, 2014 (E–028–2015–0–US–01); 2. International Patent Application PCT/US2015/062269, filed November 24, 2015 (E–028–2015–1–PCT–01); VerDate Sep<11>2014 17:23 Feb 06, 2019 Jkt 247001 3. Australian Patent Application 2015353720, filed May 18, 2017 (E–028– 2015–1–AU–02); 4. Canadian Patent Application 2968399, filed May 18, 2017 (E–028– 2015–1–CA–03); 5. Chinese Patent Application 201580070673.7, filed June 23, 2017 (E– 028–2015–1–CN–04); 6. European Patent Application 15807756.0 filed June 23, 2017 (E–028– 2015–1–EP–05); 7. Israeli Patent Application 252258, filed May 14, 2017 (E–028–2015–1–IL– 06); 8. Japanese Patent Application 527874/2017, filed May 24, 2017 (E– 028–2015–1–JP–07); 9. Korean Patent Application 2017– 7017289, filed June 23, 2017 (E–028– 2015–1–KR–08); 10. Mexican Patent Application MX/ a/2017/006865, filed May 25, 2017 (E– 028–2015–1–MX–09); 11. New Zealand Patent Application 732045, filed May 18, 2017 (E–028– 2015–1–NZ–10); 12. Saudi Arabian Patent Application 517381608, filed May 25, 2017 (E–028– 2015–1–SA–11); 13. Singapore Patent Application 11201704155U, filed May 23, 2017 (E– 028–2015–1–SG–12); 14. United States Utility Patent Application 15/528,813, filed May 23, 2017 (E–028–2015–1–US–13); and 15. Hong Kong Patent Application 18103250.9, filed March 7, 2018 (E– 028–2015–1–HK–14). E–180–2015: Anti-Mutated KRAS T Cell Receptors 1. US Provisional Patent Application 62/171,321, filed June 5, 2015 (E–180– 2015–0–US–01). E–265–2015: T Cell Receptors Recognizing HLA–CW8 Restricted Mutated KRAS 1. US Provisional Patent Application 62/218,688, filed September 15, 2015 (E–265–2015–0–US–01); 2. International Patent Application PCT/US2016/050875, filed September 9, 2016 (E–265–2015–0–PCT–02); 3. Australian Patent Application 2016323017, filed March 6, 2018 (E– 265–2015–0–AU–03); 4. Canadian Patent Application 2998869, filed March 15, 2018 (E–265– 2015–0–CA–04); 5. Chinese Patent Application 201680058891.3, filed April 3, 2018 (E– 265–2015–0–CN–05); 6. European Patent Application 16770408.9 filed March 7, 2018 (E–265– 2015–0–EP–06); 7. Israeli Patent Application 257840, filed March 4, 2018 (E–265–2018–0–IL– 07); PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 2537 8. Japanese Patent Application 513423/2018, filed March 13, 2018 (E– 265–2015–0–JP–08); 9. Korean Patent Application 2018– 7010326, filed April 12, 2018 (E–265– 2015–0–KR–09); 10. Mexican Patent Application MX/ a/2018/003062, filed March 12, 2018 (E– 265–2015–0–MX–10); 11. New Zealand Patent Application 740714, filed March 14, 2018 (E–265– 2015–0–NZ–11); 12. Saudi Arabian Patent Application 518391109, filed March 13, 2018 (E– 265–2015–0–SA–12); 13. Singapore Patent Application 11201802069U, filed March 13, 2018 (E–265–2015–0–SG–13); and 14. United States Utility Patent Application 15/758,954, filed March 9, 2018 (E–265–2015–0–US–14). E–175–2016: Anti-KRAS G12D T Cell Receptors 1. US Provisional Patent Application 62/369,883, filed August 2, 2016 (E– 175–2016–0–US–01); and 2. International Patent Application PCT/US2017/044615, filed July 31, 2017 (E–175–2016–0–PCT–02). E–181–2017: HLA Class II-Restricted T Cell Receptors Against Mutated RAS 1. US Provisional Patent Application 62/560,930, filed September 20, 2017 (E–181–2017–0–US–01); 2. International Patent Application PCT/US2018/051641, filed September 19, 2018 (E–181–2017–0–PCT–02); 3. Argentine Patent Application P180102695, filed September 20, 2018 (E–181–2017–0–AR–03); 4. Taiwan Patent Application 107133221, filed September 20, 2018 (E–181–2017–0–TW–05); and 5. United States Utility Patent Application 16/135,231, filed September 19, 2018 (E–181–2017–0– US–06). E–239–2017: HLA Class I-Restricted T Cell Receptors Against Mutated RAS 1. US Provisional Patent Application 62/594,244, filed December 4, 2017 (E– 239–2017–0–US–01); and 2. International Patent Application PCT/US2018/063581, filed December 3, 2018 (E–239–2017–0–PCT–02). E–166–2018: HLA–A3-Restricted T Cell Receptors Against Mutated RAS 1. US Provisional Patent Application 62/749,750, filed October 24, 2018 (E– 166–2018–0–US–01). E:\FR\FM\07FEN1.SGM 07FEN1

Agencies

[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Pages 2536-2537]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01412]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Improving Implementation of Seek, Test, Treat & 
Retain Strategies among People Who Inject Drugs in Low to Middle 
Income Countries (R01--Clinical Trial Required).
    Date: February 19, 2019.
    Time: 10:00 p.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
hiromi.ono@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and

[[Page 2537]]

Addiction Research Programs, National Institutes of Health, HHS)

    Dated: February 1, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-01412 Filed 2-6-19; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.